467 related articles for article (PubMed ID: 19299472)
1. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations.
Thomson AH; Staatz CE; Tobin CM; Gall M; Lovering AM
J Antimicrob Chemother; 2009 May; 63(5):1050-7. PubMed ID: 19299472
[TBL] [Abstract][Full Text] [Related]
2. Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) programme.
Lamont E; Seaton RA; Macpherson M; Semple L; Bell E; Thomson AH
J Antimicrob Chemother; 2009 Jul; 64(1):181-7. PubMed ID: 19411678
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
4. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
Schaedeli F; Uehlinger DE
Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
[TBL] [Abstract][Full Text] [Related]
5. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients.
Eiland LS; English TM; Eiland EH
Ann Pharmacother; 2011 May; 45(5):582-9. PubMed ID: 21521865
[TBL] [Abstract][Full Text] [Related]
6. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software.
Nunn MO; Corallo CE; Aubron C; Poole S; Dooley MJ; Cheng AC
Ann Pharmacother; 2011 Jun; 45(6):757-63. PubMed ID: 21652786
[TBL] [Abstract][Full Text] [Related]
7. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15-20 mg/L suggested by the vancomycin consensus guidelines.
Kullar R; Leonard SN; Davis SL; Delgado G; Pogue JM; Wahby KA; Falcione B; Rybak MJ
Pharmacotherapy; 2011 May; 31(5):441-8. PubMed ID: 21923425
[TBL] [Abstract][Full Text] [Related]
8. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
9. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients.
Dailly E; Le Floch R; Deslandes G; Pannier M; Jolliet P
Int J Antimicrob Agents; 2008 Jun; 31(6):537-9. PubMed ID: 18462925
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin pharmacokinetics in patients with severe burn injuries.
Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetic analysis of vancomycin in patients with gram-positive infections and the influence of infectious disease type.
Yamamoto M; Kuzuya T; Baba H; Yamada K; Nabeshima T
J Clin Pharm Ther; 2009 Aug; 34(4):473-83. PubMed ID: 19583681
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
Yang RH; Rong XZ; Hua R; Zhang T
Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
[TBL] [Abstract][Full Text] [Related]
13. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.
Lodise TP; Patel N; Lomaestro BM; Rodvold KA; Drusano GL
Clin Infect Dis; 2009 Aug; 49(4):507-14. PubMed ID: 19586413
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients.
Medellín-Garibay SE; Ortiz-Martín B; Rueda-Naharro A; García B; Romano-Moreno S; Barcia E
J Antimicrob Chemother; 2016 Feb; 71(2):471-9. PubMed ID: 26568565
[TBL] [Abstract][Full Text] [Related]
15. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
Nomura K; Morikawa N; Ikawa K; Ikeda K; Fujimoto Y; Shimizu D; Taniguchi K; Shimura K; Kanbayashi Y; Komori T; Matsumoto Y; Fujita N; Shimazaki C; Taniwaki M
J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
[TBL] [Abstract][Full Text] [Related]
16. A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Ralph LD; Thomson AH; Dobbs NA; Twelves C
Cancer Chemother Pharmacol; 2003 Jul; 52(1):34-40. PubMed ID: 12764671
[TBL] [Abstract][Full Text] [Related]
17. Initial vancomycin dosing protocol to achieve therapeutic serum concentrations in patients undergoing hemodialysis.
Zelenitsky SA; Ariano RE; McCrae ML; Vercaigne LM
Clin Infect Dis; 2012 Aug; 55(4):527-33. PubMed ID: 22573855
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.
Staatz CE; Byrne C; Thomson AH
Br J Clin Pharmacol; 2006 Feb; 61(2):164-76. PubMed ID: 16433871
[TBL] [Abstract][Full Text] [Related]
19. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
Brown DL; Lalla CD; Masselink AJ
Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
[TBL] [Abstract][Full Text] [Related]
20. Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.
Pryka RD; Rodvold KA; Garrison M; Rotschafer JC
Ther Drug Monit; 1989; 11(4):450-4. PubMed ID: 2741194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
